A Study Assessing Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter

Overview

The purpose of this study is to assess the performance and safety for the use of the investigational catheter for intracardiac mapping in the atria and ventricles.

Full Title of Study: “Clinical Evaluation of Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 24, 2022

Interventions

  • Device: Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter
    • Participants scheduled to have a clinically-indicated catheter mapping and ablation procedure using globe-shaped, high-density, multi-electrode mapping catheter for management of atrial procedure (scar-related atrial tachycardia, persistent atrial fibrillation, paroxysmal atrial fibrillation) and Ventricular procedures (ventricular tachycardia, premature ventricular complex).

Arms, Groups and Cohorts

  • Experimental: Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter
    • Participants with cardiac arrhythmias/ablation history who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for atrial and ventricular procedures will be using multi-electrode mapping catheter.

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants with Pre-ablation Mapping Performed Successfully with the Globe-Shaped, High-Density Multi-electrode Mapping Catheter Without Resort to Non-study Mapping Catheter
    • Time Frame: For 1 day on the day of procedure (anytime during the study duration of 6 months)
    • Number of participants with pre-ablation mapping performed successfully with the globe-shaped, high-density multi-electrode mapping catheter without resort to non-study mapping catheter will be reported. Pre-ablation mapping is considered complete when all of the following are accomplished, as applicable: 1) The entire chamber and areas associated with the targeted arrhythmia(s) are completely mapped using Fast Anatomical Mapping (FAM); 2) Substrate or previous lesion line associated with the arrhythmia(s) is mapped: a) Substrate Voltage mapping recommended for re-do Atrial Fibrillation (AF), Persistent Atrial Fibrillation (PsAF) and Ventricular Tachycardia (VT) procedures; b) Local activation mapping recommended for complex Atrial Tachycardia (AT) and VT procedures; 3) Conduction channel, gap(s) and critical isthmus are identified (as applicable); 4) Mapping density at the areas of interests (example slow conduction zones) is adequate, as assessed by the investigator.
  • Number of Participants with Clinically Indicated Mapping Performed Successfully with the Globe-Shaped, High-Density Multi-electrode Mapping Catheter Without Resort to Non-study Mapping Catheter
    • Time Frame: Up to 6 months
    • Number of participants with clinically indicated mapping performed successfully with the globe-shaped, high-density multi-electrode mapping catheter without resort to non-study mapping catheter will be reported.
  • Number of Participants with Serious Adverse Events (SAEs) within 7 days of Index Procedure Related to the Investigational Catheter
    • Time Frame: Up to 7 days of index procedure
    • Number of participants with SAEs within 7 days of index procedure related to the investigational catheter will be reported. A serious adverse device effect is an adverse device effect that has resulted in any of the consequences characteristic of an SAE. A SAE is any event that meets one or more of the following criteria: a) leads to death; b) leads to a serious deterioration in the health of a participant that resulted in: i) life-threatening illness or injury; ii) an injury or permanent impairment of a body structure or a body function; iii) in-participant hospitalization or prolongation of an existing hospitalization; iv) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function; v) chronic disease; d) leads to fetal distress, fetal death or a congenital abnormality or birth defect.

Secondary Measures

  • Physician Assessment of Deployment, Maneuverability, and Signal Quality Acquired with the Globe-shaped, High-density Multi-electrode Mapping Catheter for Mapping in the Atria and Ventricles Using a Physician-completed Survey
    • Time Frame: Up to 6 months
    • Physician assessment of deployment, maneuverability, and signal quality acquired with the globe-shaped, high-density multi-electrode mapping catheter for mapping in the atria and ventricles using a physician-completed survey will be reported. A post-procedure survey of 11 questions, each with individual sub-questions will be administered. Each question/sub-question will be answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent) and will be summarized.
  • Number of Participants with Other SAEs (Excluding Globe-shaped, High-density Multi-electrode Mapping Catheter Related SAE) within 7 days of Index Procedure
    • Time Frame: Up to 7 days of index procedure
    • Number of Participants with other SAEs (excluding globe-shaped, high-density multi-electrode mapping catheter related SAE) within 7 days of index procedure will be reported. A serious adverse device effect is an adverse device effect that has resulted in any of the consequences characteristic of an SAE. A SAE is any event that meets one or more of the following criteria: a) leads to death; b) leads to a serious deterioration in the health of a participant that resulted in: i) life-threatening illness or injury; ii) an injury or permanent impairment of a body structure or a body function; iii) in-participant hospitalization or prolongation of an existing hospitalization; iv) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function; v) chronic disease; d) leads to fetal distress, fetal death or a congenital abnormality or birth defect.
  • Number of Participants with Non-serious Adverse Events within 7 days of Index Procedure Related to the Globe-shaped, High-density Multi-electrode Mapping Catheter
    • Time Frame: Up to 7 days of index procedure
    • Number of participants with non-serious adverse events within 7 days of index procedure related to the globe-shaped, high-density multi-electrode mapping catheter will be reported.

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosed with and candidate for clinically-indicated catheter mapping and ablation procedure for the management of ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation (participants having undergone a previous ablation procedure may be included) – At least one episode of the targeted arrhythmia (ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation) must have been documented by electrocardiogram (ECG), Holter, loop recorder, telemetry, implanted device, or transtelephonic monitoring within 12 months of enrollment – Signed participants Informed Consent Form (ICF) – Able and willing to comply with all pre-, post-, and follow-up testing and requirements Exclusion Criteria:

  • Diagnosed with an arrhythmia requiring epicardial mapping – Study arrhythmia secondary to reversible cause, or secondary to electrolyte imbalance, thyroid disease, or non-cardiac cause – Atrial arrhythmias: participants with a left atrial size greater than (>) 55 millimeters (mm) – Left Ventricular Ejection Fraction (LVEF) less than or equal to (<=) 25 percent (%) for participants with ventricular arrhythmia – LVEF <= 40% for participants with atrial arrhythmia – Documented intracardiac thrombus as detected on imaging within 24 hours prior to insertion of the investigational catheter – Contraindication to anticoagulation (that is heparin, warfarin, dabigatran) – History of blood clotting or bleeding abnormalities (example, hypercoagulable state) – Myocardial infarction within the past 2 months (60 days) – Documented thromboembolic event (including Transient Ischemic Attack [TIA]) within the past 12 months (365 days) – Uncontrolled heart failure or New York Heart Association (NYHA) function class IV – Implanted with a pacemaker or intracardiac cardiac defibrillator within the past 6 weeks (42 days) – Implanted with a prosthetic valve – Active illness or active systemic infection or sepsis – Diagnosed atrial or ventricular myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation – Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study – Participants that have ever undergone a percutaneous or surgical valvular cardiac procedure (that is, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) – Any cardiac surgery within the past 60 days (2 months) (includes Percutaneous Coronary Intervention [PCI]) – Atrial septal closure within the past 6 weeks (42 days) – Presence of a condition that precludes vascular access – Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation – Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being – Concurrent enrollment in an investigational study evaluating another device or drug

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Biosense Webster, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Biosense Webster, Inc. Clinical Trial, Study Director, Biosense Webster, Inc.
  • Overall Contact(s)
    • Nathalie Macours, +32 479 97 05 05, nmacours1@its.jnj.com

References

Bick RL, Frenkel EP. Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy. Clin Appl Thromb Hemost. 1999 Oct;5 Suppl 1:S7-15. Review.

Cox B, Durieux ME, Marcus MA. Toxicity of local anaesthetics. Best Pract Res Clin Anaesthesiol. 2003 Mar;17(1):111-36. Review.

Gruchalla RS. 10. Drug allergy. J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S548-59. Review.

Mertes PM, Laxenaire MC. Allergic reactions occurring during anaesthesia. Eur J Anaesthesiol. 2002 Apr;19(4):240-62. Review.

Morcos SK, Thomsen HS, Webb JA; Contrast Media Safety Committee of the European Society of Urogenital Radiology. Prevention of generalized reactions to contrast media: a consensus report and guidelines. Eur Radiol. 2001;11(9):1720-8. Review.

Lin, A.C. and D.J. Wilber, Complications Associated With Radiofrequency Catheter Ablation, in Radiofrequency catheter ablation of cardiac arrhythmias: basic concepts and clinical applications, S.K. Huang and D.J. Wilber, Editors. 2000, Futura: Armonk, N.Y. p. 737-746.

Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol. 2000 Jun;23(6):1020-8.

Mar PL, Chong L, Perez A, Lakkireddy D, Gopinathannair R. Entrapment of diagnostic catheter within Advisor HD grid mapping catheter. J Cardiovasc Electrophysiol. 2021 Mar;32(3):860-861. doi: 10.1111/jce.14893. Epub 2021 Jan 28.

Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. J Arrhythm. 2017 Oct;33(5):369-409. doi: 10.1016/j.joa.2017.08.001. Epub 2017 Sep 15.

Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 Feb;3(1):32-8. doi: 10.1161/CIRCEP.109.859116. Epub 2009 Dec 7.

Gerstenfeld EP, Guerra P, Sparks PB, Hattori K, Lesh MD. Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. J Cardiovasc Electrophysiol. 2001 Aug;12(8):900-8.

Kovoor P, Ricciardello M, Collins L, Uther JB, Ross DL. Risk to patients from radiation associated with radiofrequency ablation for supraventricular tachycardia. Circulation. 1998 Oct 13;98(15):1534-40.

Nahass GT. Fluoroscopy and the skin: implications for radiofrequency catheter ablation. Am J Cardiol. 1995 Jul 15;76(3):174-6. Review.

Calkins H, Niklason L, Sousa J, el-Atassi R, Langberg J, Morady F. Radiation exposure during radiofrequency catheter ablation of accessory atrioventricular connections. Circulation. 1991 Dec;84(6):2376-82.

Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, Aguinaga L, Leite LR, Al-Khatib SM, Anter E, Berruezo A, Callans DJ, Chung MK, Cuculich P, d'Avila A, Deal BJ, Della Bella P, Deneke T, Dickfeld TM, Hadid C, Haqqani HM, Kay GN, Latchamsetty R, Marchlinski F, Miller JM, Nogami A, Patel AR, Pathak RK, Sáenz Morales LC, Santangeli P, Sapp JL, Sarkozy A, Soejima K, Stevenson WG, Tedrow UB, Tzou WS, Varma N, Zeppenfeld K; ESC Scientific Document Group . 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace. 2019 Aug 1;21(8):1143-1144. doi: 10.1093/europace/euz132. Erratum in: Europace. 2019 Aug 1;21(8):1144. J Arrhythm. 2020 Jan 12;36(1):214. Europace. 2020 Mar 1;22(3):505.

Raymond JM, Sacher F, Winslow R, Tedrow U, Stevenson WG. Catheter ablation for scar-related ventricular tachycardias. Curr Probl Cardiol. 2009 May;34(5):225-70. doi: 10.1016/j.cpcardiol.2009.01.002. Review.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.